Peptides

Details Peptides Peptides

2001-06-27

2004-09-21

Low, Christopher S. F. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S014800, C530S300000, C530S327000, C530S344000, C530S345000, C435S069700, C435S320100, C435S252300, C536S023400, C536S023500

Reexamination Certificate

active

06794361

ABSTRACT:

The present invention relates to novel peptides and derivatives thereof useful as inhibitors of neuronal amine transporters of neurotransmitters such as noradrenaline, serotonin, dopamine, glutamic acid and glycine. The invention also relates to pharmaceutical compositions comprising these peptides, nucleic acid probes useful in finding active analogues of these peptides, assays for finding compounds having neuronal noradrenaline transporter inhibitory activity and the use of these peptides in the prophylaxis or treatment of conditions such as but not limited to incontinence, cardiovascular conditions and mood disorders.
The marine snails of the genus Conus (cone snails) use a sophisticated biochemical strategy to capture their prey. As predators of either fish, worms or other molluscs, the cone snails inject their prey with venom containing a cocktail of small bioactive peptides. These toxin molecules, which are referred to as conotoxins, interfere with neurotransmission by targeting a variety of receptors and ion-channels. The venom from any single Conus species may contain more than 100 different peptides. The conotoxins are divided into classes on the basis of their physiological targets. To date, ten classes have been described. The &ohgr;-conotoxin class of peptides target and block voltage-sensitive Ca
2+
-channels inhibiting neurotransmitter release. The &agr;-conotoxins and &psgr;-conotoxins target and block nicotinic ACh receptors, causing ganglionic and neuromuscular blockade. Peptides of the &mgr;-conotoxin class act to block voltage-sensitive Na
+
-channels inhibiting muscle and nerve action potentials. The &dgr;-conotoxins target and delay the inactivation of voltage-sensitive Na
+
-channels, enhancing neuronal excitability. The &kgr;-conotoxin class of peptides target and block voltage-sensitive K
+
-channels, and these also cause enhanced neuronal excitability. The conopressins are vasopressin receptor antagonists and the conantokins are NMDA receptor antagonists. More recently, the prototype of a new &ggr;-conotoxin class, which targets a voltage-sensitive nonspecific cation channel, and of a new &sgr;-conotoxin class, which antagonises the 5HT
3
receptor, have been described.
It has now been found that a new class of conotoxin exists, hereinafter referred to as the &khgr;-conotoxin class, which are characterised by having the ability to inhibit neuronal amine transporters.
Compounds which inhibit neurotransmitter reuptake have been found to be useful in the treatment of lower urinary tract disorders, such as urinary incontinence, detrusor instability and interstitial cystitis. One such compound is “imipramine” which, in addition to inhibiting noradrenaline reuptake, has been shown to affect calcium channel blockade, and to exhibit anticholinergic, local anaesthetic activity and a number of other effects. Other compounds capable of inhibiting noradrenaline reuptake are described in U.S. Pat. No. 5,441,985. These compounds are said to have a reduced anticholinergic effect relative to imipramine.
In the case of the peptides of the present invention this inhibition of neurotransmitter reuptake is achieved by selectively inhibiting the neuronal neurotransmitter transporter, such as the noradrenaline transporter, which functions to rapidly clear released noradrenaline from the synapse back into neurons.
The peptides of the present invention are the first peptides to have activity in inhibiting an amine transporter. All other conotoxin peptides characterised to date target ion channels or receptors on cell surfaces.
According to one aspect of the present invention there is provided an isolated, synthetic or recombinant &khgr;-conotoxin peptide having the ability to inhibit a neuronal amine transporter.
Preferably, the neuronal amine transporter is the neuronal noradrenaline transporter.
The &khgr;-conotoxin peptide may be a naturally occurring peptide isolated from a cone snail, or a derivative thereof.
Preferably the &khgr;-conotoxin peptide is &khgr;-MrIA or &khgr;-MrIB, or a derivative thereof. &khgr;-MrIA and &khgr;-MrIB may be isolated from the venom of the mollusc hunting cone snail,
Conus marmoreus.
They are both peptides of 13 amino acid residues in length, and contain 2-disulphide bonds; the peptides show most homology to members in the &agr;-conotoxin class, which act as nicotinic ACh receptor antagonists.
The amino acid sequences of &khgr;-MrIA and &khgr;-MrIB are as follows:
&khgr;-MrIA NGVCCGYKLCHOC SEQ ID NO. 1
&khgr;-MrIB VGVCCGYKLCHOC SEQ ID NO. 2
The C-terminus may be a free acid or amidated.
In the sequences above the “O” refers to 4-hydroxy proline (Hyp). This amino acid residue results from post translational modification of the encoded peptide and is not directly encoded by the nucleotide sequence.
Preferably, the &khgr;-conotoxin peptide is a selective inhibitor of the neuronal noradrenaline transporter. The terms “selective” and “selectively” as used herein mean that the activity of the peptide as an inhibitor of neuronal noradrenaline transporter is considerably greater than any activity at the &agr;
1
-adrenoceptors.
U.S. Pat. No. 5,441,985 indicates that inhibitors of noradrenaline reuptake which have a negligible anticholinergic effect are particularly useful in the treatment of lower urinary tract disorders. It has been found that &khgr;-MrIA also has no detectable anticholinergic effect.
Accordingly in a preferred embodiment of the invention there is provided an isolated, synthetic or recombinant &khgr;-conotoxin peptide having the ability to selectively inhibit neuronal noradrenaline transporter, and having negligible or no anticholinergic effect.
&khgr;-MrIA has also been found to have no activity as a sodium channel blocker or as an inhibitor of dopamine transporter. The absence in &khgr;-MrIA of these additional pharmacological activities commonly associated with other noradrenaline transporter inhibitors and in preferred peptides according to the invention, makes these peptides useful pharmacological tools.
The &khgr;-conotoxin peptides according to the invention may be naturally occurring peptides, such as &khgr;-MrIA and &khgr;-MrIB, or may be derivatives of naturally occurring peptides.
The term “derivative” as used herein in connection with naturally occurring &khgr;-conotoxin peptides, such as &khgr;-MrIA and &khgr;-MrIB, refers to a peptide which differs from the naturally occurring peptides by one or more amino acid deletions, additions, substitutions, or side-chain modifications. Such derivatives which do not have the ability to inhibit neuronal noradrenaline transporter do not fall within the scope of the present invention.
Substitutions encompass amino acid alterations in which an amino acid is replaced with a different naturally-occurring or a non-conventional amino acid residue. Such substitutions may be classified as “conservative”, in which case an amino acid residue contained in a polypeptide is replaced with another naturally-occurring amino acid of similar character either in relation to polarity, side chain functionality or size, for example Ser⇄Thr⇄Pro⇄Hyp⇄Gly⇄Ala, Val⇄Ile⇄Leu, His⇄Lys⇄Arg, Asn⇄Gln⇄Asp⇄Glu or Phe⇄Trp⇄Tyr. It is to be understood that some non-conventional amino acids may also be suitable replacements for the naturally occurring amino acids. For example ornithine, homoarginine and dimethyllysine are related to His, Arg and Lys.
Substitutions encompassed by the present invention may also be “non-conservative”, in which an amino acid residue which is present in a peptide is substituted with an amino acid having different properties, such as naturally-occurring amino acid from a different group (eg. substituting a charged or hydrophobic amino acid with alanine), or alternatively, in which a naturally-occurring amino acid is substituted with a non-conventional amino acid.
Amino acid substitutions are typically of single residues, but may be of multiple residues, either clustered or dispersed.
Pref

Affiliated with

Also associated with

Rating

Peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3242684